Anti-Hu CD30 APC

• Description:

  CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153) . The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response.

• Certification:

  RUO

• Reactivity:

  Human

• Target Antigen:

  CD30

• Clone:

  Ber-H8

• Applications:

  FC (QC tested)

• Format:

  APC

• Buffer:

  Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

• References & Citations:

  *Aalberse JA, Kapitein B, de Roock S, Klein MR, de Jager W, van der Zee R, Hoekstra MO, van Wijk F, Prakken BJ: Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60) . PLoS One. 2011;6 (9) :e24119., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=aalberse+ja+kapitein+b+de+roock+s , *Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85 (1) :1-14., URL: http://www.ncbi.nlm.nih.gov/pubmed/7803786 , *Berro AI, Perry GA, Agrawal DK: Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004 Aug 1;173 (3) :2174-83., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=berro+ai+perry+ga , *Franke AC, Jung D, Ellis TM: Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma. 2000 Feb;19 (1) :43-8., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=franke+ac+jung+d+ellis+tm , *Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004 Feb 15;172 (4) :2186-93., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=matsumoto+k+terakawa+m+miura+k

• Other References:

  *Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007 Apr;282 (14) :10252-62. , URL: https://www.ncbi.nlm.nih.gov/pubmed/17261581?ordin, *Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007 Mar 1;109 (5) :2225-33., URL: https://www.ncbi.nlm.nih.gov/pubmed/17068147?ordin, *Kusanovic JP, Romero R, Hassan SS, Gotsch F, Edwin S, Chaiworapongsa T, Erez O, Mittal P, Mazaki-Tovi S, Soto E, Than NG, Friel LA, Yoon BH, Espinoza J: Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med. 2007 Aug 28:1-12, URL: https://www.ncbi.nlm.nih.gov/pubmed/17853188?ordin, *Bekiaris V, Withers D, Glanville SH, McConnell FM, Parnell SM, Kim MY, Gaspal FM, Jenkinson E, Sweet C, Anderson G, Lane PJ: Role of CD30 in B/T segregation in the spleen. J Immunol. 2007 Dec 1;179 (11) :7535-43., URL: https://www.ncbi.nlm.nih.gov/pubmed/18025198?ordin, *Polte T, Behrendt AK, Hansen G: Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol. 2006 Oct;118 (4) :942-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/17030250?ordin, *Kennedy MK, Willis CR, Armitage RJ: Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006 Jun;118 (2) :143-52., URL: https://www.ncbi.nlm.nih.gov/pubmed/16771849?ordin, *Fischer M, Harvima IT, Carvalho RF, Möller C, Naukkarinen A, Enblad G, Nilsson G: Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006 Oct;116 (10) :2748-56., URL: https://www.ncbi.nlm.nih.gov/pubmed/16964309?ordin, *Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, Roskos M, Serody JS, Yagita H, Podack ER, Taylor PA: CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 2004 Sep 1;173 (5) :2933-41., URL: https://www.ncbi.nlm.nih.gov/pubmed/15322151?ordin

• Storage Conditions:

  Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

• Specificity:

  The mouse monoclonal antibody Ber-H8 recognizes extracellular part of CD30 (Ki-1 antigen), a 105 kDa single chain glycoprotein expressed on Hodgkin's and Reed-Sternberg cells; it is also found in Burkitt's lymphomas, virus-infected T and B lymphocytes, and on normal B and T lymphocytes after activation (T lymphocytes that produce Th2-type cytokines and on CD4+/CD8+ T lymphocytes that co-express CD45RO and the IL4 receptor) .

• Applications Notes:

  6

• Isotype:

  Mouse IgG1 kappa